Showing results (11-20 of 264) with videos related to
Sort By:
Pageof 27
Expert Opinion on Biological Therapy|July 1, 2015
Personalized immunotherapy ( AGS-003 ) when combined with sunitinib for the treatment of metastatic renal cell carcinomaRobert A FiglinNature Clinical Practice. Oncology|July 9, 2008
Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCCRobert A FiglinExpert Opinion on Pharmacotherapy|December 4, 2009
Pazopanib: therapeutic developmentsSuwicha Limvorasak, Edwin M PosadasAnti-Cancer Agents in Medicinal Chemistry|November 21, 2009
Kinase inhibitors in prostate cancerSuwicha Limvorasak, Edwin M PosadasCancer|May 30, 2009
Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinomaAnil Kapoor, Robert A FiglinThe Journal of Urology|October 20, 2009
Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitorsCamillo Porta, Robert A FiglinOncology (Williston Park, N.Y.)|October 12, 2007
Evolving role of novel targeted agents in renal cell carcinomaThomas E Hutson, Robert A FiglinClinical Advances in Hematology & Oncology : H&O|April 20, 2010
Renal cell carcinoma therapy in 2010: many options with little comparative dataSumanta Kumar Pal, Robert A FiglinAmerican Journal of Therapeutics|January 6, 2004
The emerging role of bisphosphonates in prostate cancerEdwin M Posadas, William L Dahut, James GulleyCurrent Opinion in Oncology|August 18, 2004
Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literatureEdwin M Posadas, Ben Davidson, Elise C KohnPageof 27